Cello Therapeutics Received IND Clearance by FDA for its First-in-Class Cellular Nanoparticle (CNP) based Immunotherapy, CE120, to Enter Clinical Phase.
On November 30, 2023, Cello Therapeutics, Inc. received IND clearance from the U.S. Food and Drug Administration (FDA) for its first immunotherapy nanoformulation CE120 to initiate first-in-human clinical trials for a variety of solid tumors. CE120 is the first innovative nanomedicine cleared for clinical trials that employs platelet membrane-coated nanoparticles for drug delivery, offering a […]